Key facts
- What it is: Humanin is a small mitochondrial-derived peptide first identified through research on neuronal survival.
- Evidence: Strong mechanistic interest, predominantly cell and animal evidence.
- Status: Experimental mitochondrial-derived peptide.
- Main caution: There is no established therapeutic safety profile, standardized clinical product, or validated dosing framework.
- Sources: 5 PubMed-indexed papers linked below.
What is Humanin?
Humanin is a small mitochondrial-derived peptide first identified through research on neuronal survival. It is produced from a short open reading frame within mitochondrial ribosomal RNA and has been studied as a stress-response signal. No humanin product is approved as an anti-aging, metabolic, or neuroprotective therapy.
The first SEO trap with peptide content is treating every compound as if it belongs to the same category. It does not. Some peptides are approved prescription medicines supported by randomized trials; others are endogenous signaling molecules being studied in cells; others are unapproved chemicals sold with no regulated manufacturing chain. For Humanin, the evidence and regulatory category above determine what conclusions are reasonable.
This guide does not provide a dose, cycle, protocol, source, or personal recommendation. It translates published research so readers can distinguish a measured result from a marketing claim and bring better questions to a licensed clinician.
How does Humanin work?
Laboratory studies describe anti-apoptotic signaling, including interference with Bax activation and interactions with IGF-binding proteins. Humanin analogs also affect metabolic and inflammatory pathways in models. These overlapping actions are scientifically interesting but make a single clinical claim difficult to isolate.
Mechanism is not the same as clinical benefit. A compound can activate a receptor, change a biomarker, or improve an animal model without improving how people feel, function, or survive. The strongest medical claims require controlled human outcomes, not a plausible pathway alone.
What does the research on Humanin show?
Foundational cell studies showed protection against several Alzheimer-related toxic insults, and later work expanded into metabolic, vascular, and reproductive models. Human studies are mostly observational measurements of circulating humanin rather than intervention trials proving that supplementation changes disease outcomes.
These papers were selected to show the shape of the evidence: foundational biology, clinical trials where they exist, safety signals, and reviews that place single studies in context. A citation does not mean PepMate endorses a treatment; it lets readers inspect the original record.
How strong is the evidence?
Evidence assessment: Strong mechanistic interest, predominantly cell and animal evidence. Protecting cultured cells or improving a mouse disease model is an early translational step. Delivery, tissue exposure, target engagement, and long-term safety remain unresolved in humans.
Evidence strength depends on study design, directness, replication, sample size, and whether researchers measured a meaningful outcome. Animal evidence can justify a human trial, but it cannot establish a human treatment. Observational human data can identify associations, but it cannot reliably prove cause and effect.
Is Humanin approved or available?
Experimental mitochondrial-derived peptide. Approval is tied to a specific product, indication, population, formulation, and regulator. “Research use only,” clinic availability, compounding, or a listing on a peptide website is not the same as approval. Availability can change, so current regulator labeling and professional guidance take priority over any static article.
Humanin safety, risks, and evidence gaps
There is no established therapeutic safety profile, standardized clinical product, or validated dosing framework. Growth and survival pathways can have context-dependent effects, and online products may not contain what their labels claim.
Protecting cultured cells or improving a mouse disease model is an early translational step. Delivery, tissue exposure, target engagement, and long-term safety remain unresolved in humans.
Unapproved online peptides add risks that a paper about a verified laboratory compound cannot measure: mislabeling, contamination, sterility failure, degradation, and a concentration different from the label. Even an endogenous or short peptide can cause harm when the route, exposure, or manufacturing quality changes.
Frequently asked questions
What is Humanin?
Humanin is a small mitochondrial-derived peptide first identified through research on neuronal survival. It is produced from a short open reading frame within mitochondrial ribosomal RNA and has been studied as a stress-response signal. No humanin product is approved as an anti-aging, metabolic, or neuroprotective therapy.
How does Humanin work?
Laboratory studies describe anti-apoptotic signaling, including interference with Bax activation and interactions with IGF-binding proteins. Humanin analogs also affect metabolic and inflammatory pathways in models. These overlapping actions are scientifically interesting but make a single clinical claim difficult to isolate.
Is Humanin FDA-approved?
Experimental mitochondrial-derived peptide. Approval is indication-specific and can differ by country; check current regulator labeling rather than relying on peptide-shop descriptions.
What does PubMed research on Humanin show?
Foundational cell studies showed protection against several Alzheimer-related toxic insults, and later work expanded into metabolic, vascular, and reproductive models. Human studies are mostly observational measurements of circulating humanin rather than intervention trials proving that supplementation changes disease outcomes.
What are the main risks of Humanin?
There is no established therapeutic safety profile, standardized clinical product, or validated dosing framework. Growth and survival pathways can have context-dependent effects, and online products may not contain what their labels claim.
PubMed sources
Every medical claim in this guide is anchored to peer-reviewed or scholarly literature indexed on PubMed. Open the abstracts below to review the study design, population, and limitations.
- A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. — PubMed 11371646 (2001)
- Humanin peptide suppresses apoptosis by interfering with Bax activation. — PubMed 12732850 (2003)
- Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. — PubMed 14561895 (2003)
- Humanin: a harbinger of mitochondrial-derived peptides? — PubMed 23402768 (2013)
- A Review on the Potential Role of Humanin Peptide and its Analogs in the Regulation of Autophagy Pathways for Therapeutic Application in Metabolic Disorders. — PubMed 39950467 (2025)
Source selection and update method: PepMate Research Editorial Policy. Last updated 22 July 2026.